EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 4.0

Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis

Linda T H Godding, Marieke M B Seyger, Albert Duvetorp, Marisol E Otero, Paul M Ossenkoppele, Annet M Oostveen, M Birgitte Visch, Ella A M Van der Voort, John E M Körver, Lizelotte J M T Weppner-Parren, Maartje A M Berends, W Peter Arnold und 15 weitere

Acta Dermato-Venereologica · 2025

DOI: 10.2340/actadv.v105.42767 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Linda T H Godding und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands. linda.godding@radboudumc.nl. Hauptthemen laut MEDLINE: Psoriasis, Drug Costs, Biological Products, Dermatologic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17- and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab’s and ustekinumab’s originator prices because of biosimilar availability, adalimumab showed the lowest 1-year CPR across all responder definitions. Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab. Overall, the cost-per-PASI ≤ 3-responder was, across all biologics, more homogeneous than the CPR based on relative PASIs. Similar patterns were seen when using Swedish prices, which are, in contrast to Dutch prices, transparent. The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisDrug CostsBiological ProductsDermatologic AgentsHumansSeverity of Illness IndexTreatment OutcomeCost-Benefit AnalysisBiosimilar PharmaceuticalsTime FactorsInterleukin-23

Substanzen

Biological ProductsDermatologic AgentsBiosimilar PharmaceuticalsInterleukin-23

Autor:innen und Institutionen

  • Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands. linda.godding@radboudumc.nl.
  • Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Leo Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Sciences Malmö, Lund University, Lund, Sweden; Department…
  • Department of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, The Netherlands.
  • Department of Dermatology, Gelre Ziekenhuizen, Apeldoorn/Zutphen, The Netherlands.
  • Department of Dermatology, Ziekenhuis Rijnstate, Arnhem, The Netherlands.

Zitieren

APA

Godding, L. T. H., Seyger, M. M. B., Duvetorp, A., Otero, M. E., Ossenkoppele, P. M., Oostveen, A. M., Visch, M. B., Van der Voort, E. A. M., Körver, J. E. M., Weppner-Parren, L. J. M. T., Berends, M. A. M., Arnold, W. P., Dodemont, S. R. P., Kuijpers, A. L. A., Mommers, J. M., Homan, F. M., Gostynski, A. H., Velstra, B., Kleinpenning, M. M., …, & Van den Reek, J. M. P. A. (2025). Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.42767

Vancouver

Godding LTH, Seyger MMB, Duvetorp A, Otero ME, Ossenkoppele PM, Oostveen AM, et al. Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.42767

BibTeX
@article{Godding2025,
  author = {Godding, Linda T H and Seyger, Marieke M B and Duvetorp, Albert and Otero, Marisol E and Ossenkoppele, Paul M and Oostveen, Annet M and Visch, M Birgitte and Van der Voort, Ella A M and Körver, John E M and Weppner-Parren, Lizelotte J M T and Berends, Maartje A M and Arnold, W Peter and Dodemont, Sharon R P and Kuijpers, Astrid L A and Mommers, Johannes M and Homan, Femke M and Gostynski, Antoni H and Velstra, Berit and Kleinpenning, Marloes M and Van Doorn, Martijn B A and Keijsers, Romy R M C and Kop, Else N and Haeck, Inge M and Hendricksen-Roelofzen, Judith H J and Vellinga, Douwe and De Jong, Elke M G J and Van den Reek, Juul M P A},
  title = {Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis},
  journal = {Acta Dermato-Venereologica},
  year = {2025},
  doi = {10.2340/actadv.v105.42767}
}
Kostenlos starten →